-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Assumes Xenon Pharmaceuticals at Buy, Announces Price Target of $73

Benzinga·10/06/2026 12:14:06
Guggenheim analyst Delma Caiati assumes Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy rating and announces Price Target of $73.